Navigation Links
Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology
Date:12/7/2008

--Complete Remissions Achieved with Voreloxin in Poor Risk Frontline Elderly AML and in Combination with Cytarabine in Relapsed/Refractory AML-

--Conference Call Scheduled for Tuesday, December 9 at 11:00 am ET to Discuss Phase 2 Study Results in AML--

SAN FRANCISCO, Dec. 7 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the presentation of new data from two ongoing clinical trials demonstrating that the company's novel drug candidate, voreloxin, shows promising safety and efficacy results both in patients with newly diagnosed and relapsed/refractory acute myeloid leukemia (AML). These data were presented today at two poster sessions at the 50th Annual Meeting of the American Society of Hematology in San Francisco. The presentations are highlighted below.

Phase 2 Study of Voreloxin as Single Agent Therapy (REVEAL-1 Trial)

Interim data from the REVEAL-1 (Response Evaluation of VorEloxin in AmL) single agent Phase 2 trial show that voreloxin induces complete remissions in poor risk frontline elderly AML patients who are unlikely to benefit from standard induction chemotherapy. Many older AML patients cannot tolerate or do not respond well to standard induction chemotherapy. In Schedule A, 29 patients with a median age of 75 were enrolled and treated with 72 mg/m(2) of voreloxin weekly for three weeks. Eleven patients achieved a complete remission (CR) or complete remission without full platelet recovery (CRp) for an overall remission rate of 38 percent. An additional 5 patients had bone marrow blast reductions to less than 5 percent. The median duration of response for patients achieving a CR or CRp has not been reached.

Grade 3 or higher non-hematologic adverse event
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH
2. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
3. SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases
4. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
5. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
6. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
7. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
8. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
9. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
10. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
11. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014  RESMED INC. (NYSE: RMD ) today ... year 2015 results on Thursday, January 22, 2015, after the ... ResMed,s results will be issued after 1:00 p.m. US Pacific ... operating results and future outlook. The earnings call ... and the live webcast of the call can be accessed ...
(Date:12/19/2014)... 18, 2014   Aratana Therapeutics, Inc . ... focused on the licensing, development and commercialization of ... results from its pivotal field study of AT-001 ... in dogs with osteoarthritis.  In the study, dogs ... that were statistically significant compared to placebo (p<0.05) ...
(Date:12/17/2014)... and SAN DIEGO , Dec. 17, 2014 ... ; AEX: PHIA) and Volcano Corporation (NASDAQ: VOLC ... for cardiovascular applications, today announced that they have entered into ... commence a tender offer to acquire all of the issued ... or a total equity purchase price of USD 1 billion ...
Breaking Medicine Technology:ResMed To Announce Second Quarter 2015 Results 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8
... Spanish drug companies face a number of obstacles ...  From regulatory (FDA) and GMP compliance, to distribution agreements ... areas that must be coordinated.  Those issues have just ... U.S. company VPCI have entered into a joint association. ...
... Sherpa Clinical Packaging, a privately held provider of ... cutting ceremony today to mark the opening of ... San Diego, CA.  Sherpa,s employees and invited guests ... adjacent to the Althea Technologies campus in Sorrento ...
Cached Medicine Technology:Spanish Drug Companies Have New Support Option for the U.S. Market 2Sherpa Clinical Packaging Completes New Production Facility 2
(Date:12/21/2014)... The number of Mirena lawsuits ( ... underway in New Jersey, Bernstein Liebhard LLP reports. , ... involving the birth control IUD have now been filed ... by women who allege spontaneous migration of the device, ... and other complications they were inadequately warned about by ...
(Date:12/21/2014)... SCI explores disability in ... systemic barriers for disabled athletes with Aaron Scheidies ... a condition called juvenile macular degeneration, where he loses ... adapted his athletic ambitions to his vision and how ... to pioneer the way for other blind and visually ...
(Date:12/21/2014)... Concept Plus, LLC. a SDB and 8(a) ... VA., today announced it has been recognized by Washington ... ranks the fastest growing government contracting small businesses by calculating ... This is the first year that Concept Plus, LLC., participated ... a 95.92% compound annual growth rate. “For Concept Plus to ...
(Date:12/20/2014)... 2014 An improving macroeconomic landscape and ... the Massage Services industry over the five ... products, the anticipated 1.0% annualized increase in per capita ... with the means to afford additional massages. “While the ... in a given year has declined from 2009 to ...
(Date:12/20/2014)... December 20, 2014 Recently, VogueQueen.com, a ... VogueQueen Big Sale Online for 2015. Great ... All new and old consumers can get a discount, ... at the company’s website before January 30, 2015. , ... dresses and launched a prom dress promotion. Many customers ...
Breaking Medicine News(10 mins):Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 3Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 3Health News:Concept Plus, LLC. Named One of Washington Technology’s Fast 50 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:VogueQueen Big Sale Online For The Coming 2015 2
... ... their Third Party Assurance Program (TPAP) for clients located in the both the United States ... a want or a need, it is a biological imperative!" states Theresa M. Erickson, Surrogacy ... ...
... ... online tool for health care consumers to track essential health care readings such as blood ... over time and communicate their health data to their health care providers. , ... Cleveland, OH (PRWEB) June 3, 2009 -- ...
... at the University of Cincinnati (UC) have discovered a protein ... the rare lung disease Idiopathic Pulmonary Fibrosis (IPF). Researchers ... predictors and could lead to better decisions about treatment and ... Kinder, MD, is published in the June 4 edition of ...
... 4 University HealthSystem Consortium (UHC) will host a Web conference ... successfully by member academic medical centers. Offered exclusively to UHC members, ... , , ... Utah , who will share how that 361-bed organization has relied ...
... , , CHICAGO, June 3 ... telemedicine services in the United States, today announced ... Verizon Wireless , the nation,s leading wireless service ... preferred network for LifeWatch,s successful remote monitoring service for ...
... 3 The following is being issued by The American ... by federally funded organizations operating in every state has had ... during a period when hospital performance improved faster than outpatient ... The annual National Healthcare Quality Report, just released by the ...
Cached Medicine News:Health News:Conceptual Options, a Center for Surrogacy & Egg Donation, Announces Third Party Assurance Program 2Health News:Conceptual Options, a Center for Surrogacy & Egg Donation, Announces Third Party Assurance Program 3Health News:New Health Monitoring and Health Tracking Website, VitalsTracker.com, Helps Health Consumers Organize Important Medical Data 2Health News:Protein may be strongest indicator of rare lung disease, study shows 2Health News:LifeWatch and Verizon Wireless to Expand Healthcare Telemedicine Solutions 2Health News:QIO Support Accelerates Hospital Improvement in Heart Care, Researchers Find 2
... This compact system provides an ... preparation in the laboratory, satellite lab ... proven HEMA-TEK staining method with wedge-smear ... delivers complete standardization in a safe ...
It is a cardio-pulmonary exercise testing device....
... has digitally-controlled drive system which eliminates ... can wear out. There are no ... and fewer drive belts - resulting ... It can carry weights up to ...
... systems feature our internationally-acclaimed algorithm that ... algorithm has a proven record for ... situations; and it's just one of ... recognized market leader in the stress ...
Medicine Products: